Chimerix Inc
$ 8.54
0.00%
17 Apr - close price
- Market Cap 801,084,000 USD
- Current Price $ 8.54
- High / Low $ 8.54 / 8.54
- Stock P/E N/A
- Book Value 1.32
- EPS -0.99
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.56 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$8.53
Quarterly Earnings
| Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-02-26 | 2024-11-07 | 2024-08-13 | 2024-05-01 | 2024-02-29 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-02 | 2022-11-03 | 2022-08-08 | 2022-05-16 |
| Reported EPS | -0.25 | -0.26 | -0.23 | -0.25 | -0.2 | -0.27 | -0.21 | -0.24 | -0.24 | 2.75 | -0.27 | -0.28 |
| Estimated EPS | -0.275 | -0.24 | -0.23 | -0.22 | -0.24 | -0.23 | -0.24 | -0.25 | -0.24 | 2.14 | -0.24 | -0.33 |
| Surprise | 0.025 | -0.02 | 0 | -0.03 | 0.04 | -0.04 | 0.03 | 0.01 | 0 | 0.61 | -0.03 | 0.05 |
| Surprise Percentage | 9.0909% | -8.3333% | 0% | -13.6364% | 16.6667% | -17.3913% | 12.5% | 4% | 0% | 28.5047% | -12.5% | 15.1515% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMRX
2026-04-02 17:09:44
This article provides an overview of Chimerix, Inc. (CMRX) stock, detailing its current price, market capitalization, and key financial metrics like P/E ratio and EPS. It highlights an AI-powered analysis with a "B" score, indicating moderate investment characteristics, and provides a 12-month price target of $7.96. The analysis also covers the stock's performance changes over various periods and technical indicators such as RSI.
2026-03-12 20:52:38
Chimerix Inc. (CMRX) is trading at $8.54 intraday on NASDAQ, presenting a potential oversold bounce opportunity with key support levels at the 50-day average of $6.67 and the 200-day average of $2.75. Meyka AI rates CMRX with a score of 67 (Grade B, HOLD suggestion), projecting a 1-year price of $7.96, a 3-year price of $12.87, and a 5-year price of $17.76. The article suggests a trade plan focusing on risk control, scaling in near the 50-day average, and using partial profit targets.
2026-02-21 06:54:01
The Smallpox Treatment Market report by DataM Intelligence analyzes trends, developments, and opportunities in the market, forecasting significant CAGR growth between 2024 and 2031. It highlights key players like SIGA Technologies Inc. and Bavarian Nordic A/S, segmenting the market by treatment type (antiviral, vaccines), administration route, and distribution channels. The report also provides a regional analysis and outlines its research methodology and comprehensive coverage.
2026-02-07 22:28:59
Chimerix Inc. shares are nearing their 52-week high, driven by a rosy financial forecast from its Japanese partner, SymBio Pharmaceuticals. SymBio projects a dramatic 197.5% increase in revenue for the 2026 fiscal year, primarily attributed to brincidofovir (SyB V-1901), suggesting substantially higher license payments for Chimerix. Domestically, Chimerix continues to focus on Temodys® for malignant glioma, with investors keenly awaiting upcoming quarterly earnings for validation of the projected growth and further regulatory updates for brincidofovir.
2026-02-07 08:31:04
Chimerix Inc. shares are nearing their 52-week high, driven by a positive financial forecast from their Japanese partner, SymBio Pharmaceuticals. SymBio projects a significant 197.5% revenue increase for fiscal year 2026, primarily due to brincidofovir, suggesting higher license payments for Chimerix. Domestically, Chimerix continues to focus on Temodys® for malignant glioma, while investors await upcoming earnings reports for signs of accelerated license revenue.
2026-01-08 22:05:00
Jazz Pharmaceuticals plc announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga brings over 25 years of commercial and operational experience, having previously served as chief operating and commercial officer at Chimerix Inc., where he led its successful acquisition by Jazz. In his new role, he will drive corporate development initiatives and strategic partnerships, building on his track record of executing significant business development deals and contributing to the launch of innovative medicines.
